Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

VYNE Therapeutics (VYNE) Receivables - Net (2017 - 2023)

VYNE Therapeutics' Receivables - Net history spans 7 years, with the latest figure at $250000.0 for Q3 2023.

  • For Q3 2023, Receivables - Net fell 46.92% year-over-year to $250000.0; the TTM value through Sep 2023 reached $250000.0, down 46.92%, while the annual FY2022 figure was $173000.0, 97.72% down from the prior year.
  • Receivables - Net reached $250000.0 in Q3 2023 per VYNE's latest filing, up from $234000.0 in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $15.8 million in Q4 2020 to a low of $105000.0 in Q1 2023.
  • Average Receivables - Net over 5 years is $5.2 million, with a median of $3.5 million recorded in 2020.
  • Peak YoY movement for Receivables - Net: surged 11617.78% in 2020, then plummeted 97.72% in 2022.
  • A 5-year view of Receivables - Net shows it stood at $135000.0 in 2019, then soared by 11617.78% to $15.8 million in 2020, then plummeted by 52.06% to $7.6 million in 2021, then tumbled by 97.72% to $173000.0 in 2022, then soared by 44.51% to $250000.0 in 2023.
  • Per Business Quant, the three most recent readings for VYNE's Receivables - Net are $250000.0 (Q3 2023), $234000.0 (Q2 2023), and $105000.0 (Q1 2023).